Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) CASQ2 Antibodies:
anti-Human CASQ2 Antibodies:
anti-Rat (Rattus) CASQ2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal CASQ2 Primary Antibody for WB - ABIN1881138
Kirchhefer, Wehrmeister, Postma, Pohlentz, Mormann, Kucerova, Müller, Schmitz, Schulze-Bahr, Wilde, Neumann: The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. in Journal of molecular and cellular cardiology 2010
Show all 2 Pubmed References
Human Monoclonal CASQ2 Primary Antibody for ELISA, WB - ABIN560181
Leatherbury, Yu, Chatterjee, Walker, Yu, Tian, Lo: A novel mouse model of X-linked cardiac hypertrophy. in American journal of physiology. Heart and circulatory physiology 2008
CASQ2-/- causes increase in calsequestrin 1 (CASQ1 (show CASQ1 Antibodies)) expression.
Calcium entry activated by ablation of both JP45 (show JSRP1 Antibodies)-CASQ1 (show CASQ1 Antibodies) and JP45 (show JSRP1 Antibodies)-CASQ2 complexes supports tetanic force development in slow twitch soleus muscles.
The minimal KEKE motif of TRN (show TNPO1 Antibodies) involved in the interactions with CSQ2, HRC (show HRC Antibodies) and RyR2 (show RYR2 Antibodies) within the Ca2 (show CA2 Antibodies)+ release units of cardiac sarcoplasmic reticulum has been defined.
While CASQ2 stabilizes RyR2 (show RYR2 Antibodies) rendering it refractory in the diastolic phase, HRC (show HRC Antibodies) enhances RyR2 (show RYR2 Antibodies) activity facilitating RyR2 (show RYR2 Antibodies) recovery from refractoriness.
Results show that CASQ2 deletion causes abnormal sarcoplasmic reticulum Ca(2 (show CA2 Antibodies)+) release and selective interstitial fibrosis in the atrial pacemaker complex, which disrupt SAN pacemaking and increase susceptibility to atrial fibrillation
Viral gene transfer of wild-type CASQ2 into the heart of R33Q mice prevents and reverts severe manifestations of catecholaminergic polymorphic ventricular tachycardia.
Cardiac hypertrophy and calcium waves in CASQ2-null cardiac muscle are governed by the ryanodine receptor (Ryr)2 Ca2+ sensor.
Expression of CASQ2-R33Q influences molecular and ultra-structural heart development; post-natal, adaptive changes appear capable of ensuring until adulthood a new pathophysiological equilibrium.
Mutant CASQ2(D307H) protein retains some of its physiological function. Its expression decreases with age and is inversely related to arrhythmia severity.
Qualitatively similar results were obtained in a hybrid strain created by crossing CASQ2 knockout mice with mice deficient in phospholamban (show PLN Antibodies).
We show for the first time a heterozygous CASQ2 variant causing autosomal dominant CPVT in a large family with a severe phenotype.
a direct interaction exists between RyR2 (show RYR2 Antibodies) and CSQ2, is reported.
induced Pluripotent Stem Cell-derived cardiomyocytes are useful for investigating the similarities/differences in the pathophysiological consequences of RyR2 (show RYR2 Antibodies) versus CASQ2 mutations underlying Catecholaminergic polymorphic ventricular tachycardia.
Mutations in the MYBPC3 (show MYBPC3 Antibodies) and CASQ2 genes and six combinations between loci in the MYBPC3 (show MYBPC3 Antibodies), MYH7 (show MYH7 Antibodies) and CASQ2 genes were responsible for cardiomyopathy risk in a studied cohort.
We observed association between a CASQ2 polymorphism and SCA due to VA in patients with CAD (show CAD Antibodies) adjusting for CHF and independent associations between CASQ2 SNPs and CHF adjusting for SCA.
The sarcoplasmic reticulum calcium content in human type II fibres is primarily determined by the CSQ1 (show CASQ1 Antibodies) abundance, and in type I fibres, by the combined amounts of both CSQ1 (show CASQ1 Antibodies) and CSQ2.
Molecular analysis of the CASQ2 gene in 43 probands with Catecholaminergic polymorphic ventricular tachycardia were performed and eight mutations in five patients, were identified.
In a consanguineous family, a novel homozygous CASQ2 mutation (p.L77P) was identified in a child with CPVT who required implantation of a cardioverter defibrillator due to episodes of syncope while on medical therapy
A review of the physiology of Casq2 in cardiac Ca2 (show CA2 Antibodies)+ handling and discuss pathophysiological mechanisms that lead to catecholaminergic polymorphic ventricular tachycardia caused by CASQ2 mutations.
patients with CASQ2-associated CPVT should be recommended to receive ICDs to prevent sudden death when medical therapy is not effective.
endogenous ankyrin repeat domain 1 protein and CASQ2 are co-enriched in piglet cardiac Purkinje cells
data shows that phosphorylated calsequestrin is required for high capacity calcium buffering and suggest that ryanodine receptor (show RYR3 Antibodies) inhibition by calsequestrin is mediated by junctin (show ASPH Antibodies)
The protein encoded by this gene specifies the cardiac muscle family member of the calsequestrin family. Calsequestrin is localized to the sarcoplasmic reticulum in cardiac and slow skeletal muscle cells. The protein is a calcium binding protein that stores calcium for muscle function. Mutations in this gene cause stress-induced polymorphic ventricular tachycardia, also referred to as catecholaminergic polymorphic ventricular tachycardia 2 (CPVT2), a disease characterized by bidirectional ventricular tachycardia that may lead to cardiac arrest.
calsequestrin 2 (cardiac muscle)
, calsequestrin, cardiac muscle isoform
, cardiac calsequestrin
, calsequestrin 2, fast-twitch, cardiac muscle
, SR calcium binding protein
, calsequestrin homologue
, calsequestrin, skeletal muscle isoform
, laminin-binding protein